Shopping Cart 0
Cart Subtotal
AED 0

Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 12845

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 25690

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 38535
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Protein Phosphatase 2A (PP2A or EC 3.1.3.16)-Pipeline Review, H2 2018

Summary

Protein Phosphatase 2A (PP2A or EC 3.1.3.16) pipeline Target constitutes close to 8 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The latest report Protein Phosphatase 2A-Pipeline Review, H2 2018, outlays comprehensive information on the Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Protein Phosphatase 2A (PP2A or EC 3.1.3.16)-Protein Phosphatase 2A (PP2A) is an enzyme encoded by the PPP2CA gene. PP2A plays important roles in regulation of cell cycle, signal transduction, cell differentiation, and transformation. Its activity is related to several diseases, including neurodegenerative diseases and cancer. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 1, 1 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Cardiovascular, Gastrointestinal, Metabolic Disorders, Ophthalmology and Respiratory which include indications Breast Cancer, Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Lung Cancer, Ovarian Cancer, Allergic Conjunctivitis, Alzheimer's Disease, Asthma, Breast Tumor, Carcinoid Tumor, Chronic Lymphocytic Leukemia (CLL), Chronic Obstructive Pulmonary Disease (COPD), Colon Cancer, Crohn's Disease (Regional Enteritis), Depression, Duodenal Cancer, Idiopathic Pulmonary Fibrosis, Insulin Resistance, Ischemic Stroke, Melanoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Myelodysplastic Syndrome, Myocardial Ischemia, Neuroblastoma, Non-Small Cell Lung Cancer, Obesity, Pancreatic Cancer, Pheochromocytoma, Post-Traumatic Stress Disorder (PTSD), Renal Cell Carcinoma, Sarcomas, Septic Shock, Small-Cell Lung Cancer, Solid Tumor, Testicular Cancer, Thymoma (Thymic Epithelial Tumor), Type 2 Diabetes, Ulcerative Colitis and Uveitis.

Furthermore, this report also reviews key players involved in Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Protein Phosphatase 2A (PP2A or EC 3.1.3.16)

- The report reviews Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics and enlists all their major and minor projects

- The report assesses Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Protein Phosphatase 2A (PP2A or EC 3.1.3.16)Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Protein Phosphatase 2A (PP2A or EC 3.1.3.16) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Protein Phosphatase 2A (PP2A or EC 3.1.3.16)-Overview

Protein Phosphatase 2A (PP2A or EC 3.1.3.16)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Protein Phosphatase 2A (PP2A or EC 3.1.3.16)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Protein Phosphatase 2A (PP2A or EC 3.1.3.16)-Companies Involved in Therapeutics Development

Ampio Pharmaceuticals Inc

Lixte Biotechnology Holdings Inc

PEP-Therapy SAS

Re-Pharm Ltd

Protein Phosphatase 2A (PP2A or EC 3.1.3.16)-Drug Profiles

LB-100-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NCE-001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PEP-010-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RP-0217-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate PP2A for Castration Resistant Prostate Cancer and Lung Cancer-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit PPP2R2A for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TD-X-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VEL-015-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Protein Phosphatase 2A (PP2A or EC 3.1.3.16)-Dormant Products

Protein Phosphatase 2A (PP2A or EC 3.1.3.16)-Product Development Milestones

Featured News & Press Releases

Nov 05, 2018: FDA approves Lixte Biotechnology's IND to conduct a phase 1b/2 trial of LB-100 in patients with myelodysplastic syndrome at Moffitt Cancer Center

Oct 09, 2018: Lixte Biotechnology files an IND with the FDA to conduct a phase 1b/2 trial of LB-100 in patients with myelodysplastic syndrome at Moffitt Cancer Center

Apr 17, 2018: PEP-Therapy, Institut Curie and Gustave Roussy Obtain 2,9 MEUR to Develop a Novel Peptide in Oncology

Feb 09, 2018: LB-100, Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, Sensitizes BCR-ABL Leukemia Stem Cells to Targeted Therapy with Tyrosine Kinase Inhibitors

Jun 13, 2017: Re-Pharm and Cresset Discovery Services to attend BIO International for partnering

Apr 17, 2017: Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, LB-100, Reported to be a Potentiator of Immunotherapy in an Animal Model

Mar 09, 2017: Late-Breaking Abstract on LB-100, Lixte Biotechnologys Protein Phosphatase 2A Inhibitor, in Combination with a PD-1 Inhibitor in an Animal Model to be Presented at the AACR Annual Meeting

Jan 04, 2017: First-In-Human Assessment of LB-100, Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, Published in Clinical Cancer Research

Nov 03, 2016: Re-Pharm to present at IDDST, Nanjing, China and available for one-to-one meetings

Mar 24, 2016: Re-Pharm compound with steroid-sparing properties granted second patent for ophthalmic indications

Feb 03, 2016: Lixte Biotechnology Holdings Lead Compound LB-100 Reported to Rapidly Improve Symptoms in a Rodent Model of Depression

Nov 24, 2015: Re-Pharm awarded patent for repurposed compound for treatment of inflammatory disorders

Nov 06, 2015: Lixte Biotechnology Holdings Announces That Its Novel Protein Phosphatase 2A Inhibitor Is Associated With Stabilization Of Several Types Of Cancer Without Dose-Limiting Toxicity

Sep 17, 2015: Lixte Biotechnology Holdings Engages BioPharmaWorks To Enhance Development Of Its Pipeline Of Novel Compounds

Feb 25, 2015: Lixte Biotechnology's Lead Compound Reported To Be Active Against Hematologic Cancers In Pre-Clinical Studies

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indications, H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Number of Products under Investigation by Universities/Institutes, H2 2018

Products under Investigation by Universities/Institutes, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by Ampio Pharmaceuticals Inc, H2 2018

Pipeline by Lixte Biotechnology Holdings Inc, H2 2018

Pipeline by PEP-Therapy SAS, H2 2018

Pipeline by Re-Pharm Ltd, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd..1), H2 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Protein Phosphatase 2A (PP2A or EC 3.1.3.16) Therapeutic Products under Development, Key Players in Protein Phosphatase 2A (PP2A or EC 3.1.3.16) Therapeutics, Protein Phosphatase 2A (PP2A or EC 3.1.3.16) Pipeline Overview, Protein Phosphatase 2A (PP2A or EC 3.1.3.16) Pipeline, Protein Phosphatase 2A (PP2A or EC 3.1.3.16) Pipeline Assessment


Companies

Ampio Pharmaceuticals Inc

Lixte Biotechnology Holdings Inc

PEP-Therapy SAS

Re-Pharm Ltd

Protein Phosphatase 2A (PP2A or EC 3.1.3.16)-Pipeline Review, H2 2018

Summary

Protein Phosphatase 2A (PP2A or EC 3.1.3.16) pipeline Target constitutes close to 8 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The latest report Protein Phosphatase 2A-Pipeline Review, H2 2018, outlays comprehensive information on the Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Protein Phosphatase 2A (PP2A or EC 3.1.3.16)-Protein Phosphatase 2A (PP2A) is an enzyme encoded by the PPP2CA gene. PP2A plays important roles in regulation of cell cycle, signal transduction, cell differentiation, and transformation. Its activity is related to several diseases, including neurodegenerative diseases and cancer. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 1, 1 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Cardiovascular, Gastrointestinal, Metabolic Disorders, Ophthalmology and Respiratory which include indications Breast Cancer, Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Lung Cancer, Ovarian Cancer, Allergic Conjunctivitis, Alzheimer's Disease, Asthma, Breast Tumor, Carcinoid Tumor, Chronic Lymphocytic Leukemia (CLL), Chronic Obstructive Pulmonary Disease (COPD), Colon Cancer, Crohn's Disease (Regional Enteritis), Depression, Duodenal Cancer, Idiopathic Pulmonary Fibrosis, Insulin Resistance, Ischemic Stroke, Melanoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Myelodysplastic Syndrome, Myocardial Ischemia, Neuroblastoma, Non-Small Cell Lung Cancer, Obesity, Pancreatic Cancer, Pheochromocytoma, Post-Traumatic Stress Disorder (PTSD), Renal Cell Carcinoma, Sarcomas, Septic Shock, Small-Cell Lung Cancer, Solid Tumor, Testicular Cancer, Thymoma (Thymic Epithelial Tumor), Type 2 Diabetes, Ulcerative Colitis and Uveitis.

Furthermore, this report also reviews key players involved in Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Protein Phosphatase 2A (PP2A or EC 3.1.3.16)

- The report reviews Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics and enlists all their major and minor projects

- The report assesses Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Protein Phosphatase 2A (PP2A or EC 3.1.3.16)Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Protein Phosphatase 2A (PP2A or EC 3.1.3.16) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Protein Phosphatase 2A (PP2A or EC 3.1.3.16)-Overview

Protein Phosphatase 2A (PP2A or EC 3.1.3.16)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Protein Phosphatase 2A (PP2A or EC 3.1.3.16)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Protein Phosphatase 2A (PP2A or EC 3.1.3.16)-Companies Involved in Therapeutics Development

Ampio Pharmaceuticals Inc

Lixte Biotechnology Holdings Inc

PEP-Therapy SAS

Re-Pharm Ltd

Protein Phosphatase 2A (PP2A or EC 3.1.3.16)-Drug Profiles

LB-100-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NCE-001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PEP-010-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RP-0217-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate PP2A for Castration Resistant Prostate Cancer and Lung Cancer-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit PPP2R2A for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TD-X-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VEL-015-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Protein Phosphatase 2A (PP2A or EC 3.1.3.16)-Dormant Products

Protein Phosphatase 2A (PP2A or EC 3.1.3.16)-Product Development Milestones

Featured News & Press Releases

Nov 05, 2018: FDA approves Lixte Biotechnology's IND to conduct a phase 1b/2 trial of LB-100 in patients with myelodysplastic syndrome at Moffitt Cancer Center

Oct 09, 2018: Lixte Biotechnology files an IND with the FDA to conduct a phase 1b/2 trial of LB-100 in patients with myelodysplastic syndrome at Moffitt Cancer Center

Apr 17, 2018: PEP-Therapy, Institut Curie and Gustave Roussy Obtain 2,9 MEUR to Develop a Novel Peptide in Oncology

Feb 09, 2018: LB-100, Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, Sensitizes BCR-ABL Leukemia Stem Cells to Targeted Therapy with Tyrosine Kinase Inhibitors

Jun 13, 2017: Re-Pharm and Cresset Discovery Services to attend BIO International for partnering

Apr 17, 2017: Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, LB-100, Reported to be a Potentiator of Immunotherapy in an Animal Model

Mar 09, 2017: Late-Breaking Abstract on LB-100, Lixte Biotechnologys Protein Phosphatase 2A Inhibitor, in Combination with a PD-1 Inhibitor in an Animal Model to be Presented at the AACR Annual Meeting

Jan 04, 2017: First-In-Human Assessment of LB-100, Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, Published in Clinical Cancer Research

Nov 03, 2016: Re-Pharm to present at IDDST, Nanjing, China and available for one-to-one meetings

Mar 24, 2016: Re-Pharm compound with steroid-sparing properties granted second patent for ophthalmic indications

Feb 03, 2016: Lixte Biotechnology Holdings Lead Compound LB-100 Reported to Rapidly Improve Symptoms in a Rodent Model of Depression

Nov 24, 2015: Re-Pharm awarded patent for repurposed compound for treatment of inflammatory disorders

Nov 06, 2015: Lixte Biotechnology Holdings Announces That Its Novel Protein Phosphatase 2A Inhibitor Is Associated With Stabilization Of Several Types Of Cancer Without Dose-Limiting Toxicity

Sep 17, 2015: Lixte Biotechnology Holdings Engages BioPharmaWorks To Enhance Development Of Its Pipeline Of Novel Compounds

Feb 25, 2015: Lixte Biotechnology's Lead Compound Reported To Be Active Against Hematologic Cancers In Pre-Clinical Studies

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indications, H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Number of Products under Investigation by Universities/Institutes, H2 2018

Products under Investigation by Universities/Institutes, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by Ampio Pharmaceuticals Inc, H2 2018

Pipeline by Lixte Biotechnology Holdings Inc, H2 2018

Pipeline by PEP-Therapy SAS, H2 2018

Pipeline by Re-Pharm Ltd, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd..1), H2 2018

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Protein Phosphatase 2A (PP2A or EC 3.1.3.16) Therapeutic Products under Development, Key Players in Protein Phosphatase 2A (PP2A or EC 3.1.3.16) Therapeutics, Protein Phosphatase 2A (PP2A or EC 3.1.3.16) Pipeline Overview, Protein Phosphatase 2A (PP2A or EC 3.1.3.16) Pipeline, Protein Phosphatase 2A (PP2A or EC 3.1.3.16) Pipeline Assessment


Companies

Ampio Pharmaceuticals Inc

Lixte Biotechnology Holdings Inc

PEP-Therapy SAS

Re-Pharm Ltd

chat_bubbleLet's Chat